AAN
Apr 19, 2024
Advancing Parkinson’s Disease Treatment: P2B001 Offers Promising Safety Profile in Early PD Patients
P2B001, a novel once-daily combination therapy, uniquely merges extended-release pramipexole and rasagiline in low doses, targeting Parkinson's Disease (PD) with enhanced efficacy and minimized side effects. The analysis presented by Pharma Two B highlighted P2B001's impressive safety and tolerability profile c...
Read More...
Apr 19, 2024
Unveiling the Promising Long-Term Potential of Subcutaneous Efgartigimod PH20 in Managing gMG
Efgartigimod PH20 is a combination subcutaneous (SC) infusion that contains efgartigimod alfa and hyaluronidase which may be used to improve muscle weakness in adults with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive. The interim results presented by Argenx highlighted notable efficac...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
